- Home
- ALZN vs APVO Comparison
ALZN vs APVO Comparison
Compare ALZN & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- APVO
- Stock Information
- Founded
- ALZN 2016
- APVO 2016
- Country
- ALZN United States
- APVO United States
- Employees
- ALZN N/A
- APVO N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- APVO Health Care
- Exchange
- ALZN Nasdaq
- APVO Nasdaq
- Market Cap
- ALZN 4.5M
- APVO 4.1M
- IPO Year
- ALZN 2021
- APVO N/A
- Fundamental
- Price
- ALZN $3.62
- APVO $4.95
- Analyst Decision
- ALZN Strong Buy
- APVO Strong Buy
- Analyst Count
- ALZN 1
- APVO 1
- Target Price
- ALZN $180.00
- APVO $5,920.00
- AVG Volume (30 Days)
- ALZN 4.6M
- APVO 392.7K
- Earning Date
- ALZN 07-29-2025
- APVO 05-14-2025
- Dividend Yield
- ALZN N/A
- APVO N/A
- EPS Growth
- ALZN N/A
- APVO N/A
- EPS
- ALZN N/A
- APVO N/A
- Revenue
- ALZN N/A
- APVO N/A
- Revenue This Year
- ALZN $322.64
- APVO N/A
- Revenue Next Year
- ALZN N/A
- APVO N/A
- P/E Ratio
- ALZN N/A
- APVO N/A
- Revenue Growth
- ALZN N/A
- APVO N/A
- 52 Week Low
- ALZN $3.06
- APVO $4.30
- 52 Week High
- ALZN $135.54
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- ALZN 42.05
- APVO 28.32
- Support Level
- ALZN $3.55
- APVO $4.30
- Resistance Level
- ALZN $4.30
- APVO $5.18
- Average True Range (ATR)
- ALZN 0.58
- APVO 1.22
- MACD
- ALZN 0.11
- APVO 0.72
- Stochastic Oscillator
- ALZN 7.44
- APVO 6.47
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.